Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 233-239

  Sarris, A H ^a   Younes, A ^a   McLaughlin, P ^a   Moore, D ^a   Hagemeister, F ^a   Swan, F ^a   Rodriguez, M A ^a   Romaguera, J ^a   North, L ^a   Mansfield, P ^a   Callendar, D ^a   Mesina, O ^a   Cabanillas, F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PACLITAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RELAPSE;

EID: 9044247075     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.233     Document Type: Article

References (45)

1. Horwitz SB, Cohen D, Rao S, et al: Taxol: Mechanisms of action and resistance. Monogr Natl Cancer Inst 1993:55-61, 1993
2. Bhalla K, Ibrado AM, Tourkina E, et al: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7:563-568, 1993
3. Liu Y, Bhalla K, Hill C, et al: Evidence for involvement of tyrosine phosphorylation in Taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol 48:1265-1272, 1994
4. Milross C, Hunter N, Mason K, et al: Dependency of antitumor effect of Taxol on its ability to induce mitotic arrest and apoptosis. Proc Am Assoc Cancer Res 36:352 1995 (abstr)
5. Wilson WH, Chabner BA, Bryant G, et al: Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13:381-386, 1995
6. Younes A, Sards A, Menlyk A, et al: Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 13:583-587, 1995
7. Shustic C, Dalton W, Gros P: P-glycoprotein-mediated multidrug resistance in tumor cells: Biochemistry, clinical relevance and modulation. Molec Aspects Med 16:1-78, 1995
8. Riordan JR, Deuchars K, Kartner N, et al: Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316:817-819, 1985
9. Kartner N, Evernden PD, Bradley G, et al: Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820-823, 1985
10. Gros P, Croop J, Housman D: Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47:371-380, 1986
11. Chen CJ, Chin JE, Ueda K, et al: Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389, 1986
12. Ueda K, Cardarelli C, Gottesman MM, et al: Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84:3004-3008, 1987
13. Mickisch GH, Aksentijevich I, Schoenlein PV, et al: Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 79:1087-1093, 1992
14. Hanania EG, Deisseroth AB: Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1:21-25, 1994
15. Schinkel AH, Smit JJ, van TO, et al: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502, 1994
16. Lehnert M, Emerson S, Dalton WAS, et al: In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. Monogr Natl Cancer Inst 1993:63-67, 1993
17. Jachez B, Nordmann R, Loor F: Restoration of taxol sensitivity of multidrug-resistant cells by the cycloporin A SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 85:478-83, 1993
18. Bhalla K, Huang Y, Tang C, et al: Characterization of a human myeloid leukemia cell line highly resistant to Taxol. Leukemia 8:465-75, 1994
19. Ross HJ, Canada AL, Slater LM: Cyclosporin enhances efficacy of Taxol against human and murine aerodigestive cancers in vitro. Proc Am Assoc Cancer Res 36:344, 1995 (abstr)
20. Gayscone R, Hoskins P, Connors J, et al: A study of clinical and pathologic variables affecting disease specific survival (DSS) of patients with diffuse large cell lymphoma treated with MACOP-B or VACOP-B: Univariate and multivariate analyses. Proc Am Soc Clin Oncol 13:374, 1994 (abstr)
21. Miller TP, Grogan TM, Dalton WS, et al: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24, 1991
22. Cheng AL, Su IJ, Chen YC, et al: Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 11:109-115, 1993
23. Goldstein LJ, Gottesman MM, Pastan I: Expression of the MDR1 gene in human cancers. Cancer Treat Res 57:101-19, 1991
24. Chabner BA, Bates SE, Fojo AT, et al: Drug resistance in adult lymphomas. Semin Hematol 31:70-87, 1994
25. Yuen AR, Sikic BI: Multidrug resistance in lymphomas. J Clin Oncol 12:2453-2459, 1994
26. Yahanda AM, Alder KM, Fisher GA, et al: Phase I trial of etoposide with cycloporin A as a modulator of multidrug resistance. J Clin Oncol 10:1624-1634, 1992
27. Wilson WH, Bates S, Kang YK, et al: Reversal of multidrug resistance (mdr-1) with R-verapamil and analysis of mdr-1 expression in patients with lymphoma refractory to EPOCH chemotherapy. Proc Am Assoc Cancer Res 34:212, 1993 (abstr)
28. McLaughlin P, Hagemeister FB, Swan F, et al: Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 2:73-77, 1994
29. McLaughlin P, Hagemeister FB, Swan FJ, et al: Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-579, 1994
30. Rodriguez MA, Cabanillas FC, Velasquez W, et al: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734-1741, 1995
31. Fisher GA, Bartlett NL, Lum BL, et al: Phase I trial of Taxol (T) with high-dose cyclosporin (CsA) as a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 13:144, 1994 (abstr)
32. Merker MM, Handschumacher RE: Uptake and nature of the intracellular binding of cyclosporin A in a murine thymoma cell line, BW5147. J Immunol 132:3064-3070, 1984
33. Cooper DL, Braverman IM, Sarris AH, et al: Cyclosporin A treatment of refractory T-cell lymphomas. Cancer 71:2335-2341, 1993
34. Gan YB, Balturshot G, Millenbaum NJ, et al: P-glycoprotein expression in human tumors and its correlation with chemosensitivity to Taxol and cell mobility. Proc Am Assoc Cancer Res 36:334, 1995 (abstr)
35. Futscher BW, Campbell K, Dalton WS: Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil. Cancer Res 52:5013-5017, 1992
36. Peng Y-M, Dalton WS: Selection of methylation-variant cells and its association with an altered tumor cell phenotype. Proc Am Assoc Cancer Res 36:371, 1995 (abstr)
37. Warr JR, Brewer F, Anderson M, et al: Verapamil hypersensitivity of vincristine resistant Chinese hamster ovary cell lines. Cell Biol Int Rep 10:389-99, 1986
38. Biedler JL: Drug resistance: Genotype versus phenotype-Thirty-second G.H.A. Clowes Memorial Award Lecture. Cancer Res 54:666-678, 1994
39. Brock I, Hipfner DR, Nielsen BS, et al: Sequential coexpression of the multidrug resistance genes MRP and mdr-1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55:459-462, 1995
40. Cole SP, Sparks KE, Fraser K, et al: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910, 1994
41. Deisseroth AB, De Vita VTJ: The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. Cancer J Sci Am 1:15-21, 1995
42. Tang C, Willingham MC, Reed JC, et al: High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960-1969, 1994
43. Chin KV, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462, 1992
44. Nguyen KT, Liu B, Ueda K, et al: Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 6:71-77, 1994
45. Wilson WH, Teruya-Felstein J, Harris C, et al: P53, but not bcl-2, overexpression is independently associated with drug resistance in relapsed non-Hodgkin's lymphomas (NHL) treated with EPOCH. Proc Am Soc Clin Oncol 14:392, 1995 (abstr)